Internal Medicine
| 3 min read
Data presented at the American Heart Association’s International Stroke Conference highlight a potential shift in stroke prevention.
| 4 min read
These late-stage therapies span obesity, diabetes, hypertension, and allergy care, offering new mechanisms and delivery formats that could reshape patient treatment.
| 5 min read
After decades of slow progress, advances in molecular profiling and organoid technology are creating new pathways for non-invasive diagnosis and targeted treatment of endometriosis.
| 3 min read
Direct evidence of cardiomyocyte division in living human tissue reframes long-held assumptions about cardiac irreversibility, while underscoring how far therapies still have to go.
| 5 min read
What commercialization looks like when headcount shrinks, launches can’t miss, and geography becomes a risk decision.
| 3 min read
Tariff-free US access and pricing reforms give the UK a potential edge in an uncertain global market.
| 4 min read
Without standardized, strain-level analysis, and clinically meaningful benchmarks, microbiome science will struggle to move from research into routine care.
| 4 min read
As the FDA shifts toward nonclinical methods, scientists weigh whether alternative technologies can match the predictive power of animal studies.
| 4 min read
A new drug may restore sexual function for men for months after just three days of dosing, offering hope for those who don’t respond to existing therapies.
| 8 min read
As nearly 90 percent of drugs fail in human trials, researchers are turning to patient-derived cells, engineered tissues, and AI to better predict human responses and reduce costly late-stage failures.
| 5 min read
The life sciences sector contributes billions to the economy, but current policy and international factors are threatening growth.
| 4 min read
